Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
Dyadic International (Nasdaq: DYAI), a global biotechnology company specializing in precision engineered functional input proteins, has scheduled its second quarter 2025 financial results announcement and corporate update conference call for Wednesday, August 13, 2025, at 5:00 p.m. Eastern Time.
The company will host a conference call accessible via toll-free and international dial-in numbers, with a webcast available through their investor relations website. Participants can submit questions for the Q&A session by emailing them in advance.
Dyadic International (Nasdaq: DYAI), un'azienda biotecnologica globale specializzata in proteine funzionali di precisione, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 e un aggiornamento aziendale tramite conference call per mercoledì 13 agosto 2025, alle 17:00 ora Eastern.
L'azienda terrà una conference call accessibile tramite numeri verdi e numeri internazionali, con una diretta web disponibile sul sito web delle relazioni con gli investitori. I partecipanti potranno inviare domande per la sessione di Q&A via email in anticipo.
Dyadic International (Nasdaq: DYAI), una compañía biotecnológica global especializada en proteínas funcionales de precisión, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 y una actualización corporativa mediante una llamada conferencia para el miércoles 13 de agosto de 2025 a las 5:00 p.m. hora del Este.
La compañía realizará una llamada conferencia accesible mediante números gratuitos y números internacionales, con una transmisión en vivo disponible en su sitio web de relaciones con inversionistas. Los participantes podrán enviar preguntas para la sesión de preguntas y respuestas por correo electrónico con anticipación.
Dyadic International (Nasdaq: DYAI)는 정밀 설계된 기능성 입력 단백질을 전문으로 하는 글로벌 생명공학 회사로, 2025년 2분기 재무 실적 발표 및 기업 업데이트 컨퍼런스 콜을 2025년 8월 13일 수요일 오후 5시(동부 시간)에 예정했습니다.
회사는 무료 전화 및 국제 전화 접속 번호를 통해 컨퍼런스 콜을 진행하며, 투자자 관계 웹사이트를 통해 웹캐스트도 제공할 예정입니다. 참가자들은 사전에 이메일로 질문을 제출하여 Q&A 세션에 참여할 수 있습니다.
Dyadic International (Nasdaq : DYAI), une entreprise biotechnologique mondiale spécialisée dans les protéines fonctionnelles d'entrée à précision conçue, a programmé l'annonce des résultats financiers du deuxième trimestre 2025 et une mise à jour d'entreprise lors d'une conférence téléphonique prévue pour le mercredi 13 août 2025 à 17h00 heure de l'Est.
L'entreprise organisera une conférence téléphonique accessible via des numéros gratuits et internationaux, avec une diffusion en direct disponible sur leur site web des relations investisseurs. Les participants peuvent soumettre leurs questions pour la session de questions-réponses par email à l'avance.
Dyadic International (Nasdaq: DYAI), ein globales Biotechnologieunternehmen, das sich auf präzise entwickelte funktionelle Eingabeproteine spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 sowie ein Unternehmensupdate per Telefonkonferenz für Mittwoch, den 13. August 2025, um 17:00 Uhr Eastern Time geplant.
Das Unternehmen wird eine Telefonkonferenz mit gebührenfreien und internationalen Einwahlnummern veranstalten, zudem wird ein Webcast über die Investor-Relations-Website verfügbar sein. Teilnehmer können ihre Fragen für die Fragerunde im Voraus per E-Mail einreichen.
- None.
- None.
JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the second quarter 2025 and host a corporate update conference call on Wednesday, August 13, 2025.
Conference Call Information
Date: Wednesday, August 13, 2025
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560
Conference ID: 13751388
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1706019&tp_key=4747da0ef3. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email jlavalley@dyadic.com prior to the conference call.
About Dyadic Applied BioSolutions
Dyadic Applied BioSolutions is a global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets. These high-quality proteins are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, and are the foundation of a growing portfolio of commercial and partnered programs.
For more information, visit www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic Applied BioSolutions
Ping Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
FAQ
When will Dyadic (DYAI) report its Q2 2025 earnings?
How can investors access Dyadic's Q2 2025 earnings call?
What is the conference ID for Dyadic's Q2 2025 earnings call?
How can investors submit questions for Dyadic's Q2 2025 earnings call?
Where can investors find the replay of Dyadic's Q2 2025 earnings call?
